State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer.
This review focuses on the transformative impact of antibody-drug conjugates (ADCs), specifically enfortumab vedotin and...
Germline Testing: The Therapeutic Biomarker You Can’t Afford to Miss
- Post category:Breast Cancer/Digestive (CRC, Stomach) System/Genitourinary (Prostate, Bladder) System/Gynecologic Cancer/Melanoma/Respiratory (Lung, Bronchus) System
- Reading time:2 mins read
You may already be ordering germline testing at rates well above the national average — but across the U.S., most eligible patients still aren’t tested: Ovarian cancer: ~39% receive germline…
Advancing Bladder Cancer Management: The Role of Neoadjuvant and Adjuvant Therapies and Biomarkers in Muscle Invasive Bladder Cancer.
- Post category:Genitourinary (Prostate, Bladder) System
- Reading time:1 min read
This publication reviews the rapidly evolving management of muscle-invasive bladder cancer (MIBC), highlighting the crit...
Muscle-Invasive Bladder Cancer: A Watershed Moment.
- Post category:Genitourinary (Prostate, Bladder) System
- Reading time:1 min read
The management of muscle-invasive bladder cancer (MIBC) has significantly advanced, particularly recognizing the challen...
SEOM-SOGUG clinical guideline for urothelial cancer (2025).
- Post category:Genitourinary (Prostate, Bladder) System
- Reading time:1 min read
This 2025 clinical guideline offers evidence-based recommendations for the diagnosis, staging, and management of bladder...
The Immunotherapy Clock Has Moved
- Post category:Breast Cancer/Genitourinary (Prostate, Bladder) System/Head & Neck Cancers/Pan Cancer/Respiratory (Lung, Bronchus) System/Supportive Oncology/Survivorship
- Reading time:3 mins read
Checkpoint inhibitors are no longer reserved for late-stage salvage. The clearest signal from recent meetings and trials is this: the greatest survival benefit may be increasingly found in neoadjuvant and perioperative settings. This…